Concepedia

Matthew Renschler

MR

Statistics

Publications

4

Citations

203

H-Index

4

Active since

2018

Affiliations

Eli Lilly (United States)(Current)

Matthew Renschler is an author at Eli Lilly (United States) specializing in pharmacology, oncology, and medicine.

Publications per year

2018–2019

4

Publications

4

Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models

Caitlin D. Lowery, Michele Dowless, Matthew Renschler et al. · Clinical Cancer Research · 2018 · 80 citations · Full text

Medicine, Oncology, Pharmacology +17

Abemaciclib Is Active in Preclinical Models of Ewing Sarcoma via Multipronged Regulation of Cell Cycle, DNA Methylation, and Interferon Pathway Signaling

Michele Dowless, Caitlin D. Lowery, Terry J. Shackleford et al. · Clinical Cancer Research · 2018 · 69 citations

Medicine, Oncology, Pharmacology +17

Using nitrous acid-modified de Man, Rogosa, and Sharpe medium to selectively isolate and culture lactic acid bacteria from dairy foods

Matthew Renschler, Asia Wyatt, Nnamdi Anene et al. · Journal of Dairy Science · 2019 · 36 citations · Full text

Agriculture, Food Science, Microbiology +13

Anti-VEGFR2 therapy delays growth of preclinical pediatric tumor models and enhances anti-tumor activity of chemotherapy

Caitlin D. Lowery, Wayne Blosser, Michele Dowless et al. · Oncotarget · 2019 · 18 citations · Full text

Medicine, Oncology, Pharmacology +17

1–4 of 4